Stay updated on Filgotinib Long-term Extension in Psoriatic Arthritis Clinical Trial
Sign up to get notified when there's something new on the Filgotinib Long-term Extension in Psoriatic Arthritis Clinical Trial page.

Latest updates to the Filgotinib Long-term Extension in Psoriatic Arthritis Clinical Trial page
- Check6 days agoChange DetectedThe page changed from a 403 Forbidden screen to the ClinicalTrials.gov record for the filgotinib long-term extension study in psoriatic arthritis, showing the study details and its terminated status.SummaryDifference58%

- Check13 days agoChange DetectedThe footer’s site revision label changed from v3.7.2 to v3.8.0, while the study record continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoChange DetectedA banner announces NIH’s transition-related updates and says the term “Super Intelligence” is being used in place of “Artificial Intelligence.” It appears above the study page’s 403 error message.SummaryDifference1%

- Check27 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.SummaryDifference0.2%

- Check34 days agoChange DetectedThe site footer’s revision label changed from v3.7.0 to v3.7.1 while the study page continued to display a 403 Forbidden error.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study record content with an access-denied screen. This indicates the page is not currently accessible to users.SummaryDifference18%

Stay in the know with updates to Filgotinib Long-term Extension in Psoriatic Arthritis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Filgotinib Long-term Extension in Psoriatic Arthritis Clinical Trial page.